Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices

Professional Development

Q&A discussion with Ben Goldacre

A single tabletop microphone stands in front of abstract data charts and an open book.

Q&A discussion with Ben Goldacre takes place on 25 October 2017 in the Barclay Room, Green Templeton College. This Professional Development event from the Reuters Institute for the Study of Journalism features Ben Goldacre, author of Bad Science and director of EBM DataLab, Nuffield Dept Primary Care.

Hosted with: Psychedelic Writers Guild